{
    "id": 2916,
    "fullName": "PDGFB over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PDGFB over exp indicates an over expression of the Pdgfb protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5155,
        "geneSymbol": "PDGFB",
        "terms": [
            "PDGFB",
            "c-sis",
            "IBGC5",
            "PDGF-2",
            "PDGF2",
            "SIS",
            "SSV"
        ]
    },
    "variant": "over exp",
    "createDate": "01/08/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1602,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment in a rat model of cholangiocarcinoma, which overexpressed the PDGF-BB homodimer, resulted in increased tumor cell apoptosis, and decreased tumor growth and metastasis (PMID: 22133064).",
            "molecularProfile": {
                "id": 2739,
                "profileName": "PDGFB over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1622,
                    "pubMedId": 22133064,
                    "title": "Targeting PDGFR-\u03b2 in Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22133064"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3855,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, advanced medullary thyroid cancer patients with high baseline Pdgfb expersssion were more likely to display tumor reduction when treated with Lenvima (lenvatinib) (PMID: 26311725).",
            "molecularProfile": {
                "id": 2739,
                "profileName": "PDGFB over exp"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4237,
                    "pubMedId": 26311725,
                    "title": "A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311725"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Adavosertib (MK-1775) induced apoptosis of mouse proneural glioblastoma cells lacking TP53 and PTEN and over expressing PDGFB in cell culture (PMID: 27196784).",
            "molecularProfile": {
                "id": 24369,
                "profileName": "PDGFB over exp PTEN del TP53 del"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 50804,
                "name": "glioblastoma proneural subtype",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6050,
                    "pubMedId": 27196784,
                    "title": "Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2739,
            "profileName": "PDGFB over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 3406,
                    "name": "PDGFR-beta Inhibitor",
                    "profileName": "PDGFB over exp"
                },
                {
                    "id": 3407,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "PDGFB over exp"
                }
            ]
        },
        {
            "id": 24369,
            "profileName": "PDGFB over exp PTEN del TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}